Cancer UrologyCancer UrologyОнкоурология1726-97761996-1812Publishing House ABV Press10910.17650/1726-9776-2011-7-1-79-84DIAGNOSIS AND TREATMENT OF URINARY SYSTEM TUMORS. URINARY BLADDER CANCERДИАГНОСТИКА И ЛЕЧЕНИЕ ОПУХОЛЕЙ МОЧЕПОЛОВОЙ СИСТЕМЫ. Рак мочевого пузыряINITIAL EXPERIENCE WITH ADJUVANT INTRAVESICAL THERMOCHEMOTHERAPY FOR NON-MUSCLE INVASIVE BLADDER CANCERНАЧАЛЬНЫЙ ОПЫТ ПРИМЕНЕНИЯ АДЪЮВАНТНОЙ ВНУТРИПУЗЫРНОЙ ТЕРМОХИМИОТЕРАПИИ ПРИ МЫШЕЧНО-НЕИНВАЗИВНОМ РАКЕ МОЧЕВОГО ПУЗЫРЯPavlenkoK. A.ПавленкоК. А.
Russian Federation
sfayrat@smtp.ruKochinA. V.КочинА. В.
Russian Federation
sfayrat@smtp.ruVolkovT. V.ВолковТ. В.
Russian Federation
sfayrat@smtp.ruDepartment of Urology, A.I. Burnazyan Federal Medical Biophysical Center, Federal Biomedical Agency of Russia, MoscowУрологическое отделение ФГУ ФМБЦ им. А.И. Бурназяна ФМБА России, Москва300320117179842707201427072014https://oncourology.abvpress.ru/oncur/article/view/109

Objective: to reveal the benefits of adjuvant intravesical thermochemotherapy (TCT) and to evaluate its efficiency in the treatment of moderateand high-risk non-muscle invasive bladder cancer (BC).

Subjects and methods. In the period 2009 to 2010, the Urology Clinic, Federal Medical Biophysical Center, treated 21 patients with nonmuscle invasive BC, by using a Thermotron RF-8 clinical hyperthermal system. Intravesical TCT with mitomycin C 40 mg for 60–80 min was performed at 42 ± 2 °С as one session weekly for 6 weeks. Control cystoscopy was carried out every 3 months.

Results. Of the 21 patients, 19 were found to tolerate the procedure well. No complications were recorded in these patients during the sessions and throughout the course of intravesical TCT. A recurrence was histologically verified in 2 patients at 6-month follow-up. There was no evidence suggesting a recurrence in 12 (57.14 %) patients at one-year follow-up. The follow-up of the other patients is now less than 12 months.

Conclusion. The proposed method of hyperthermia may be used as an alternative to the existing one of intracavitary hyperthermia to treat high- and moderate-risk BC and in case of inefficiency of other adjuvant therapy options for non-muscle invasive BC.

bladder cancertransurethral resectionrecurrencehyperthermiathermochemotherapyрак мочевого пузырятрансуретральная резекциярецидивгипертермиятермохимиотерапия1. Чиссов В.И., Старинский В.В. Состояние онкологической помощи населению России в 2009 г. М., 2010.Чиссов В.И., Старинский В.В. Состояние онкологической помощи населению России в 2009 г. М., 2010.2. Kiemeney L.A., Witjes J.A., Heijbroek A.L., Debruyne F.M. Predictability of recurrent and progressive disease in individual patients with primary superficial bladder cancer. J Urol 1993;4:150–60.Kiemeney L.A., Witjes J.A., Heijbroek A.L., Debruyne F.M. Predictability of recurrent and progressive disease in individual patients with primary superficial bladder cancer. J Urol 1993;4:150–60.3. Amling C.L. Diagnosis and management of superficial bladder cancer. Curr Probl Cancer 2001;25:219–78.Amling C.L. Diagnosis and management of superficial bladder cancer. Curr Probl Cancer 2001;25:219–78.4. Русаков И.Г., Соколов В.В., Булгакова Н.Н. и др. Фотодинамическая диагностика и флуоресцентная спектроскопия при поверхностном раке мочевого пузыря. Онкоурология 2009;4:41–6.Русаков И.Г., Соколов В.В., Булгакова Н.Н. и др. Фотодинамическая диагностика и флуоресцентная спектроскопия при поверхностном раке мочевого пузыря. Онкоурология 2009;4:41–6.5. European Association of Urology, Guidelines 2010.European Association of Urology, Guidelines 2010.6. Epidemiology, staging, grading and risk stratification of bladder cancer. Eur Urol Suppl 2008;7.Epidemiology, staging, grading and risk stratification of bladder cancer. Eur Urol Suppl 2008;7.7. Shen Z., Shen T., Wientjes M.G. et al. Intravesical treatments of bladder cancer: review. Pharm Res 2008;25(7).Shen Z., Shen T., Wientjes M.G. et al. Intravesical treatments of bladder cancer: review. Pharm Res 2008;25(7).8. Moskovitz B., Meyer G., Kravtzov A. et al. Thermo-chemotherapy for intermediate or high-risk recurrent superficial bladder cancer patients. Ann Oncol 2005;16:585–9.Moskovitz B., Meyer G., Kravtzov A. et al. Thermo-chemotherapy for intermediate or high-risk recurrent superficial bladder cancer patients. Ann Oncol 2005;16:585–9.9. Paroni R., Salonia A., Lev A. et al. Effect of local hyperthermia of the bladder on mitomycin C pharmacokinetics during intravesical chemotherapy for the treatment of superficial transitional cell carcinoma. Br J Clin Pharmacol 2001;52:273–8.Paroni R., Salonia A., Lev A. et al. Effect of local hyperthermia of the bladder on mitomycin C pharmacokinetics during intravesical chemotherapy for the treatment of superficial transitional cell carcinoma. Br J Clin Pharmacol 2001;52:273–8.10. Colombo R., Da Pazzo L.F., Lev A. et al. Neoadjuvant combined microwave induced local hyperthermia and topical chemotherapy versus chemotherapy alone for superficial bladder cancer. J Urol 1996;155:1227–32.Colombo R., Da Pazzo L.F., Lev A. et al. Neoadjuvant combined microwave induced local hyperthermia and topical chemotherapy versus chemotherapy alone for superficial bladder cancer. J Urol 1996;155:1227–32.11. Kato H., Fukuhara T., Yamamoto I. «Capacitive-type heating» in cancer treatment by hyperthermia, radiation and drugs. NY: Taylor & Francis, 1993; p. 23–36.Kato H., Fukuhara T., Yamamoto I. «Capacitive-type heating» in cancer treatment by hyperthermia, radiation and drugs. NY: Taylor & Francis, 1993; p. 23–36.12. Overgaard J. The current and potential role of hyperthermia in radiotherapy. Int J Radiat Oncol Biol Phys 1989;16:535–49.Overgaard J. The current and potential role of hyperthermia in radiotherapy. Int J Radiat Oncol Biol Phys 1989;16:535–49.13. Herman T.S., Teicher B.A., Jochelson M. et al. Rationale for use of local hyperthermia with radiation therapy and selected anticancer drugs in locally advanced human malignancies. Int J Hypertherm 1988;4:143–58.Herman T.S., Teicher B.A., Jochelson M. et al. Rationale for use of local hyperthermia with radiation therapy and selected anticancer drugs in locally advanced human malignancies. Int J Hypertherm 1988;4:143–58.14. Newsam J.E., Law H.T. Hyperthermic perfusion of the distended urinary bladder in the management of recurrent transitional cell carcinoma: a review after 6 years. Br J Urol 1982;54:64–5.Newsam J.E., Law H.T. Hyperthermic perfusion of the distended urinary bladder in the management of recurrent transitional cell carcinoma: a review after 6 years. Br J Urol 1982;54:64–5.15. Meyer J.L. The clinical efficacy of localized hyperthermia. Cancer Res 1984;44(Suppl 10):4745–51.Meyer J.L. The clinical efficacy of localized hyperthermia. Cancer Res 1984;44(Suppl 10):4745–51.16. Komatsu K., Miller R.C., Hal E.J. The oncogenic potential of combination of hyperthermia and chemotherapy agents. Br J Cancer 1988;57:59–63.Komatsu K., Miller R.C., Hal E.J. The oncogenic potential of combination of hyperthermia and chemotherapy agents. Br J Cancer 1988;57:59–63.17. Coley W.B. The treatment of malignant tumors by repeated inoculations of erysipelas with a report of 10 original cases. Am J Med Sci 1891;488.Coley W.B. The treatment of malignant tumors by repeated inoculations of erysipelas with a report of 10 original cases. Am J Med Sci 1891;488.18. Matzkin H., Rangel M.C., Soloway M.C. In vitro study of the effect of hyperthermia on normal bladder cancer cell line and on five different transitional cell carcinoma cell lines. J Urol 1992;147:1671.Matzkin H., Rangel M.C., Soloway M.C. In vitro study of the effect of hyperthermia on normal bladder cancer cell line and on five different transitional cell carcinoma cell lines. J Urol 1992;147:1671.19. Van der Heijden A.G., Jansen C.F.J., Verhaegh G. The effect of hyperthermia on mitomycin-C induced cytotoxicity in four human bladder cancer cell lines. Eur Urol 2004;46(5):670–4.Van der Heijden A.G., Jansen C.F.J., Verhaegh G. The effect of hyperthermia on mitomycin-C induced cytotoxicity in four human bladder cancer cell lines. Eur Urol 2004;46(5):670–4.20. Van der Heijden A.G., Verhaegh G., Jansen C.F.J. et al. Effect of hyperthermia on the cytotoxicity of 4 chemotherapeutic agents currently used for the treatment of transitional cell carcinoma of the bladder: an in vitro study. J Urol 2005;173:1375–80.Van der Heijden A.G., Verhaegh G., Jansen C.F.J. et al. Effect of hyperthermia on the cytotoxicity of 4 chemotherapeutic agents currently used for the treatment of transitional cell carcinoma of the bladder: an in vitro study. J Urol 2005;173:1375–80.21. Colombo R., Da Pozzo L.F., Salonia A. et al. Multicentric study comparing intravesical chemotherapy alone and with local microwave hyperthermia for prophylaxis of recurrence of superficial transitional cell carcinoma. J Clin Oncol 2003;21:4270–6.Colombo R., Da Pozzo L.F., Salonia A. et al. Multicentric study comparing intravesical chemotherapy alone and with local microwave hyperthermia for prophylaxis of recurrence of superficial transitional cell carcinoma. J Clin Oncol 2003;21:4270–6.22. Van der Heijden A.G., Kiemeney L.A., Gofrit O.N. et al. Preliminary European results of local microwave hyperthermia and chemotherapy treatment in intermediate or high risk superficial transitional cell carcinoma of the bladder. Eur Urol 2004;46:65–71.Van der Heijden A.G., Kiemeney L.A., Gofrit O.N. et al. Preliminary European results of local microwave hyperthermia and chemotherapy treatment in intermediate or high risk superficial transitional cell carcinoma of the bladder. Eur Urol 2004;46:65–71.23.Witjes J.A., Hendriksen K., Gofrit O. et al. Intravesical hyperthermia and mitomycin-C for carcinoma in situ of the urinary bladder: experience of the European Synergo working party. World J Urol 2009.Witjes J.A., Hendriksen K., Gofrit O. et al. Intravesical hyperthermia and mitomycin-C for carcinoma in situ of the urinary bladder: experience of the European Synergo working party. World J Urol 2009.